-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The combination of dabrafenib and trametinib has been approved by the US FDA , the European Society and the Australian TGA for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation, and as an adjuvant therapy for resected BRAF V600 Mutant stage 3 melanoma and BRAF V600 mutant advanced non-small cell lung cancer ( NSCLC ).
In addition, this combination program has also been approved by the FDA and TGA for the treatment of BRAF V600 mutant undifferentiated thyroid cancer
.
Fever is a common adverse event in patients receiving dabrafenib combined with trametinib
.
This article describes the acceptance of tadalafil Nepal + incidence in patients treated with imatinib Qumei fever, models and in clinical trials management situation
management
A total of 1,075 patients receiving dabrafenib combined with trametinib in clinical trials were included: 82 advanced NSCLC (phase 2 trial), 435 resectable stage 3 melanomas (phase 3 COMBI-AD study) , 209 unresectable melanomas (phase 3 COMBI-d study) and 350 metastatic melanomas (phase 3 COMBI-v study)
.
Proportion of patients with different repetition times of fever
Proportion of patients with different repetition times of feverAmong the 1076 patients participating in the clinical trial, 61.
3% had fever, 5.
7% had grade 3/4 fever, and 15.
6% had serious fever events as defined by the agreement
.
Among the 660 patients with fever, 33.
Among the 660 patients with fever, 33.
In summary, fever is the most common adverse event in treatment with dabrafenib combined with trametinib.
Original source:
Schadendorf Dirk,Robert Caroline,Dummer Reinhard et al.
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers in this message